Search

Displaying results 3861 - 3870 of 6076 in total
  1. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  2. Drug

    Abiprubart

    go.drugbank.com/drugs/DB19333
    Investigational

    Abiprubart is being evaluated for its efficacy and safety in participants with Sjögren's Disease in clinical trial NCT06531395

  3. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  4. Drug

    Agerafenib

    go.drugbank.com/drugs/DB15068
    Investigational

    Agerafenib is under investigation in clinical trial NCT03052569 (Expanded Access to RXDX-105 for Cancers With RET Alterations).

  5. Drug

    Ibezapolstat

    go.drugbank.com/drugs/DB16189
    Investigational

    Ibezapolstat is under investigation in clinical trial NCT04247542 (ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection).

  6. Drug

    Indirubin

    go.drugbank.com/drugs/DB12379
    Investigational

    Indirubin is under investigation in clinical trial NCT01735864 (Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment).

  7. Drug

    Setipiprant

    go.drugbank.com/drugs/DB12562
    Investigational

    Setipiprant has been investigated for the treatment of Seasonal Allergic Rhinitis, asthma and scalp hair loss (Androgenetic Alopecia).

  8. Drug

    Brilacidin

    go.drugbank.com/drugs/DB12997
    Investigational

    Brilacidin is under investigation for the supportive care of Mucositis, Stomatitis, Mouth Diseases, and Head and Neck Neoplasms.

  9. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.

  10. Drug

    N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine

    go.drugbank.com/drugs/DB13948
    Experimental

    25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It...